3D Medicines Says Envafoimab Granted Orphan Drug Designation
3D Medicines Inc :ENVAFOIMAB GRANTED ORPHAN DRUG DESIGNATIONDESIGNATION FOR TREATMENT OF GASTRIC CANCER AND - GASTRO-ESOPHAGEAL JUNCTION CANCER INDICATIONS BY CHINA NMPA
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments